12.05.25 Release
Innospera Pharma to Present Key Comparative Data About Novel GPCR Modulator for IPF at ATS 2025 Annual Meeting
-
Chief Scientific Officer to Deliver Two Oral Presentations and One Poster Presentation
MONTREAL, Quebec, Canada – May 12, 2025 – Innospera Pharma Inc., (“Innospera”), a private, near-clinical-stage biotechnology company focused on developing small-molecule modulators of GPR84 and GPR40 to address a broad range of inflammatory and metabolic diseases with high unmet medical needs, today announced that its Chief Scientific Officer will participate in the upcoming American Thoracic Society (ATS) 2025 Annual Meeting, taking place May 16–21, 2025, in San Francisco, California.
As part of Innospera’s commitment to advancing novel treatments for idiopathic pulmonary fibrosis and ultimately improving patient outcomes in dire need for new options, the company will present three abstracts at the meeting, including two oral presentations and one poster presentation, highlighting new preclinical findings about ING-006, a novel GPR84/GPR40 modulator.
“We’re honoured to share our latest comparative studies about ING-006 compared to standards of care and drugs in late-stage clinical development at ATS 2025, a leading forum for respiratory innovation,” said Lyne Gagnon, PhD, Chief Scientific Officer of Innospera Pharma. “Presented data will highlight the therapeutic potential of a dual modulation of GPR84/GPR40 by a single oral drug in order to bring new treatment options in respiratory medicine.”
Presentation Details:
Oral Presentation #1: A Comparative Study With ING-006, Nintedanib, Nerandomilast and Bexotegrast Using the In Vivo CAM-Patient-Derived IPF Model
Presenter: Lyne Gagnon, CSO
Session: D98 - TRACING THE SCAR IN INTERSTITIAL LUNG DISEASES
Date & Time: Wednesday May 21, 2025, 12:00-12:12pm
Oral Presentation #2: ING-006, A Novel Oral GPR40/GPR84 Fatty Acid Receptor Modulator: A Comparative Study With Nintedanib and Nerandomilast (BI-1015550) in Bleomycin-induced Lung Fibrosis and CAM-IPF Xenograft Models
Presenter: Lyne Gagnon, CSO
Session: D98 - TRACING THE SCAR IN INTERSTITIAL LUNG DISEASES
Date & Time: Wednesday May 21, 2025, 12:12-12:24pm
Poster Presentation: ING-006 Modulation Of GPR40 And GPR84: The Bright/dark Side Targets In IPF Pathogenesis
Presenter: Lyne Gagnon, CSO
Session: C29 - READING BETWEEN THE LINES IN INTERSTITIAL LUNG DISEASE, poster board #908
Date & Time: Tuesday May 20, 2025 9:15 AM - 11:15 AM
About Innospera
Innospera is a privately-owned biotech company near clinical stage, developing small molecule modulators of 7-transmembrane receptors involved in a broad range of chronic and fibrotic conditions. The company’s lead drug candidates target key G-protein coupled receptors (GPCR) involved in fibroaging and inflammaging, including idiopathic pulmonary fibrosis (IPF), a condition with dire short-term prognosis. Innospera also develops multiple other modulators with promising potency in other medical conditions with pressing unmet needs.
$ $ $
Contact
Pierre Laurin, BPharm, MSc
Executive Chairman
Innospera Pharma inc